Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis

被引:7
|
作者
Camara-Lemarroy, Carlos [1 ,2 ,3 ]
Silva, Claudia [1 ,2 ]
Gohill, Jit [4 ]
Yong, V. Wee [1 ,2 ]
Koch, Marcus [1 ,2 ,5 ]
机构
[1] Univ Calgary, Dept Clin Neurosci, Room 178,Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
[3] UANL Sch Med, Monterrey, Mexico
[4] Univ Calgary, Dept Surg, Sect Ophthalmol, Calgary, AB, Canada
[5] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
关键词
GFAP; HCQ; multiple sclerosis; NfL; PPMS; OPTICAL COHERENCE TOMOGRAPHY; OCRELIZUMAB; PLACEBO;
D O I
10.1111/ene.15588
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate of disability worsening at 18 months in primary progressive multiple sclerosis (PPMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers in multiple sclerosis. Methods We measured NfL and GFAP levels in serum samples from 39 patients with inactive PPMS included in a phase II clinical trial of HCQ treatment in PPMS at multiple time points over 18 months, and investigated the association of these biomarkers with clinical disability at screening and during follow-up. Screening and 12-month retinal nerve fiber layer (RNFL) thickness was also recorded and analyzed. Results NfL and GFAP levels increased over time, but only significantly from screening to month 6. NfL and GFAP levels did not significantly increase from month 6 up to month 18. At screening, NfL and GFAP levels did not correlate with the Expanded Disability Status Scale (EDSS), and GFAP but not NfL modestly correlated with Timed 25-Foot Walk test (T25FW). Screening NfL and GFAP levels did not predict disability worsening (>= 20% worsening on the T25FW) at month 18. RNFL thickness decreased significantly from screening to month 12 and independently predicted disability worsening. Conclusions In this cohort of people with inactive PPMS, HCQ treatment attenuated the increase of NfL and GFAP after 6 months of treatment and up to 18 months of follow-up, suggesting a treatment effect of HCQ over these biomarkers. RNFL thickness, a marker of neuroaxonal atrophy, was associated with disability worsening, and should be explored further as a prognostic marker in this population.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 50 条
  • [31] Prognostic value of neurofilament light and glial fibrillary acidic protein for disability worsening PIRA by age range in multiple sclerosis
    Barro, C.
    Healy, B. C.
    Bose, G.
    Lokhande, H.
    Saxena, S.
    Ferreira, V. F. Moreira
    Polgar-Turcsanyi, M.
    Bakshi, R.
    Weiner, H. L.
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 306 - 306
  • [32] Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis
    Madill, Evan
    Healy, Brian C.
    Molazadeh, Negar
    Polgar-Turcsanyi, Mariann
    Glanz, Bonnie I.
    Weiner, Howard L.
    Chitnis, Tanuja
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (10): : 2719 - 2730
  • [33] Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases
    Xinqing Lin
    Tingting Lu
    Haiyi Deng
    Chunxin Liu
    Yilin Yang
    Tao Chen
    Yinyin Qin
    Xiaohong Xie
    Zhanhong Xie
    Ming Liu
    Ming Ouyang
    Shiyue Li
    Yong Song
    Nanshan Zhong
    Wei Qiu
    Chengzhi Zhou
    Journal of Neurology, 2022, 269 : 815 - 823
  • [34] Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases
    Lin, Xinqing
    Lu, Tingting
    Deng, Haiyi
    Liu, Chunxin
    Yang, Yilin
    Chen, Tao
    Qin, Yinyin
    Xie, Xiaohong
    Xie, Zhanhong
    Liu, Ming
    Ouyang, Ming
    Li, Shiyue
    Song, Yong
    Zhong, Nanshan
    Qiu, Wei
    Zhou, Chengzhi
    JOURNAL OF NEUROLOGY, 2022, 269 (02) : 815 - 823
  • [35] Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson?s disease
    Mao, Shuai
    Teng, Xing
    Li, Zhen
    Zu, Jie
    Zhang, Tao
    Xu, Chuanying
    Cui, Guiyun
    BRAIN RESEARCH, 2023, 1805
  • [36] Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
    Avasarala, JR
    NEUROLOGY, 2004, 63 (03) : 599 - 599
  • [37] Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
    Malmeström, C
    Haghighi, S
    Rosengren, L
    Andersen, O
    Lycke, J
    NEUROLOGY, 2003, 61 (12) : 1720 - 1725
  • [38] Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia
    Heller, Carolin
    Chan, Elise
    Foiani, Martha S.
    Todd, Emily
    Russell, Lucy L.
    Greaves, Caroline, V
    Heslegrave, Amanda J.
    Warren, Jason D.
    Zetterberg, Henrik
    Bocchetta, Martina
    Rohrer, Jonathan D.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (04): : 455 - 456
  • [39] Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis
    Benkert, Pascal
    Maceski, Aleksandra Maleska
    Schaedelin, Sabine
    Oechtering, Johanna
    Zadic, Amar
    Gomez, Juan Francisco Vilchez
    Melie-Garcia, Lester
    Cagol, Alessandro
    Galbusera, Riccardo
    Subramaniam, Suvitha
    Lorscheider, Johannes
    Galli, Edoardo
    Mueller, Jannis
    Fischer-Barnicol, Bettina
    Achtnichts, Lutz
    Findling, Oliver
    Lalive, Patrice H.
    Bridel, Claire
    Uginet, Marjolaine
    Mueller, Stefanie
    Pot, Caroline
    Mathias, Amandine
    Du Pasquier, Renaud
    Salmen, Anke
    Hoepner, Robert
    Chan, Andrew
    Disanto, Giulio
    Zecca, Chiara
    D'Souza, Marcus
    Hemkens, Lars G.
    Yaldizli, Ozgur
    Derfuss, Tobias
    Roth, Patrick
    Gobbi, Claudio
    Brassat, David
    Tackenberg, Bjorn
    Pedotti, Rosetta
    Raposo, Catarina
    Oksenberg, Jorge
    Wiendl, Heinz
    Berger, Klaus
    Hermesdorf, Marco
    Piehl, Fredrik
    Conen, David
    Buser, Andreas
    Kappos, Ludwig
    Khalil, Michael
    Granziera, Cristina
    Abdelhak, Ahmed
    Leppert, David
    ANNALS OF NEUROLOGY, 2025, 97 (01) : 104 - 115
  • [40] Serum neurofilament light chain but not serum glial fibrillary acidic protein is a marker of early Huntington's disease
    Heim, Beatrice
    Mandler, Elias
    Peball, Marina
    Carbone, Federico
    Schwarzova, Katarina
    Demjaha, Rina
    Tafrali, Cansu
    Buchmann, Arabella
    Khalil, Michael
    Djamshidian, Atbin
    Seppi, Klaus
    JOURNAL OF NEUROLOGY, 2025, 272 (02)